Are the positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 desirable for the treatment of atrial fibrillation?
APD prolongation and suppression of APs by XEN-D0103 at high stimulation rates in SR and pAF tissue, but not cAF, could be of therapeutic benefit for reducing AF burden. This concept needs to be confirmed in clinical trials.
Our results suggest GSTs may hold promise as therapeutic targets in more advanced prostate cancers, particularly, in African-Americans.